Immune complex vasculitis of small vessels with secondary glomerulonephritis in children
DOI:
https://doi.org/10.15574/SP.2024.140.119Keywords:
children, immunoglobulin A - vasculitis, secondary glomerulonephritis with urinary syndrome, treatmentAbstract
Immunoglobulin A - vasculitis (IgA-V) is a systemic disease with predominant damage to the microcirculatory channel of the skin, gastrointestinal tract, joints, and kidneys.
Aim - to show, on the basis of clinical observation, the features of the symptoms and course of IgA-V when the kidneys are involved in the pathological process and the complications of treatment.
Clinical case. A 5-year-old child hospitalized with a diagnosis of acute IgA-V of moderate severity: skin, joint, abdominal forms. Bed rest, symptomatic and supportive therapy were prescribed, antigenic load was excluded, pain syndrome was controlled with acetaminophen. Positive dynamics of clinical syndromes were observed. However, against the background of bed rest on the 17th day of the illness, fresh and changed erythrocytes appeared in the morning urine, covering the entire field of vision, erythrocyte cylinders (up to 30-40), protein - 0.9 g/l. In daily urine - protein - 2.0 g/day. The absence of an increase in blood pressure (BP), edema allowed to document the isolated urinary syndrome of secondary glomerulonephritis. Taking into account the severity of the urinary syndrome, prednisolone 1 mg/kg was added to the treatment complex. The lack of effectiveness of corticosteroid for 3 weeks led to the use of plasmapheresis in the children's clinic named “Protection of motherhood and childhood”, after which the number of erythrocytes decreased to 50-80 in the field of vision, erythrocyte cylinders (to 5-8). The daily protein level is up to 1.5 g/day. The child was transferred to the nephrology department, where angiotensin-converting enzyme inhibitors were prescribed under BP control against the background of corticosteroid withdrawal. Observation of the child for 3 years showed periodic exacerbations of vasculitis, which occurred against the background of acute respiratory diseases, which were manifested by a slight hemorrhagic rash on the lower extremities and changes in urine tests. The patient's BP was within normal limits. During the last year of observation, there were no exacerbations of glomerulonephritis and no skin rashes were observed.
Conclusions. IgA - vasculitis involving the kidneys in the form of hematuria and proteinuria can have a long course. Treatment of pronounced urinary syndrome should take into account the possibility of insufficient effectiveness of corticosteroid and the need to use other treatment regimens that depend on the severity of the pathological process in the kidneys. Renoprotection with angiotensin-converting enzyme inhibitors prevents secondary kidney damage.
The research was carried out in accordance with the principles of the Declaration of Helsinki. Informed consent of the child's parents was obtained for the research.
The authors declare no conflicts of interest.
References
Bista S, Adhikari Y, Karmacharya S, Joshi S, Pandey S, Adhikari N. (2023). Henoch-Schönlein purpura with antecedent allergic diseases in a 4-year-old child: a case report. Ann Med Surg (Lond). 85(6): 3066-3069. https://doi.org/10.1097/MS9.0000000000000782; PMid:37363590 PMCid:PMC10289484
Bluman J, Goldman RD. (2014). Henoch-Schönlein purpura in children: limited benefit of corticosteroids. Can Fam Physician. 60(11): 1007-1010.
Cao T, Yang HM, Huang J, Hu Y. (2023). Risk factors associated with recurrence of Henoch-Schonlein purpura: a retrospective study. Front Pediatr. 11: 1164099. https://doi.org/10.3389/fped.2023.1164099; PMid:37377759 PMCid:PMC10291609
Guo D, Lam JM. (2016). Henoch-Schönlein purpura. CMAJ. 188(15): 393. https://doi.org/10.1503/cmaj.151072; PMid:27431304 PMCid:PMC5056890
Hetland LE, Susrud KS, Lindahl KH, Bygum A. (2017). Henoch-Schönlein Purpura: A Literature Review. Acta Derm Venereol. 97(10): 1160-1166. https://doi.org/10.2340/00015555-2733; PMid:28654132
Jennette JC, Falk RJ, Bacon PA et al. (2013). 2012-revised International Сhapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65(1): 1-11. https://doi.org/10.1002/art.37715; PMid:23045170
Liu Y, Jesus AA, Marrero B et al. (2014). Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 371(6): 507-518. https://doi.org/10.1056/NEJMoa1312625; PMid:25029335 PMCid:PMC4174543
Liu Y, Ramot Y, Torrelo A et al. (2012). Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic phenotypic heterogeneity. Arthritis Rheum. 64(3): 895-907. https://doi.org/10.1002/art.33368; PMid:21953331 PMCid:PMC3278554
Navon EP, Pierce SB, Segel R et al. (2014). Mutant adenosine deaminase 2 in polyarteritis nodosa vasculopathy. N. Engl. J Med. 370(10): 921-931. https://doi.org/10.1056/NEJMoa1307362; PMid:24552285
Nguyen B, Acharya C, Tangpanithandee S, Miao J, Krisanapan P, Thongprayoon C et al. (2023). Efficacy and Safety of Plasma Exchange as an Adjunctive Therapy for Rapidly Progressive IgA Nephropathy and Henoch-Schönlein Purpura Nephritis: A Systematic Review. Int J Mol Sci. 16; 24(4). https://doi.org/10.3390/ijms24043977
Nikolaishvili M, Pazhava A, Di Lernia V. (2023). Viral Infections May Be Associated with Henoch-Schönlein Purpura. J. Clin. Med. 16; 12(2). https://doi.org/10.3390/jcm12020697; PMid:36675626 PMCid:PMC9862009
Ozen S, Marks SD, Brogan P et al. (2019). European consensus based recommendations for diagnosis and treatment of immunoglobulin A vasculitis - the SHARE initiative. Rheumatology (Oxford). 58(9): 1607-1616. https://doi.org/10.1093/rheumatology/kez041; PMid:30879080
Ozen S, Pistirio A, Iusan SM et al. (2010). EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008/ Part II: final classification crsteria. Ann. Rheum. Dis. 69: 798-806. https://doi.org/10.1136/ard.2009.116657; PMid:20413568
Piram M, Mahr A. (2013). Epidemiology of immunoglobulin A vasculitis (Henoch-Schonlein) current state of knowledge. Curr. Opin. Rheumatol. 25: 171-178. https://doi.org/10.1097/BOR.0b013e32835d8e2a; PMid:23318735
Piram M, Maldini C, Biscardi S et al. (2017). Incidence of Ig A vasculitis in children estimated by four - source capture - recapture analysis: a population - based study. Rheumatology (Oxford). 56: 1358-1366. https://doi.org/10.1093/rheumatology/kex158; PMid:28444335
Popov H, Koleva T, Stoyanov GS. (2023). Bullous Henoch-Schönlein Purpura and Associated Nephritis: A Pathological Case Report. Cureus. 15(2): 35051. https://doi.org/10.7759/cureus.35051
Rajasekaran A, Julian BA, Rizk DV. (2021). IgA Nephropathy: An Interesting Autoimmune Kidney Disease. Am J Med Sci. 361(2): 176-194. https://doi.org/10.1016/j.amjms.2020.10.003; PMid:33309134 PMCid:PMC8577278
Reamy BV, Williams PM, Lindsay TJ. (2009). Henoch-Schönlein purpura. Am. Fam. Physician. 80(7): 697-704.
Salem Y, Alam Z, Shalabi MM, Hosler GA, Acharya S. (2023). IgA Vasculitis Associated With COVID-19. Cureus. 15(5): 38725. https://doi.org/10.7759/cureus.38725
Sestan M, Jelusic M. (2023). Diagnostic and Management Strategies of IgA Vasculitis Nephritis/Henoch-Schönlein Purpura Nephritis in Pediatric Patients: Current Perspectives. Pediatric Health Med Ther. 14: 89-98. https://doi.org/10.2147/PHMT.S379862; PMid:36915829 PMCid:PMC10008002
Sugino H, Sawada Y, Nakamura M. (2021). IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes. Int. J. Mol. Sci. 22(14). https://doi.org/10.3390/ijms22147538; PMid:34299162 PMCid:PMC8307949
Trnka P. (2013). Henoch-Schönlein purpura in children. J Paediatr Child Health. 49(12): 995-1003. https://doi.org/10.1111/jpc.12403; PMid:24134307
Xu L, Li Y, Wu X. (2022). IgA vasculitis update: Epidemiology, pathogenesis, and biomarkers. Front Immunol. 13: 921864. https://doi.org/10.3389/fimmu.2022.921864; PMid:36263029 PMCid:PMC9574357
Zhou Q, Yang D, Ombrello AK et al. (2014). Early - onset strok and vasculopathy associated with mutation in ADA2. N. Engl. J Med. 370(10): 911-920.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Modern pediatrics. Ukraine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.